Pain Management

Roughly two-thirds of emergency department admissions for overdoses involve prescription opioid medications.

It is compulsory for pharmacists to counsel all patients receiving opioids, evaluate the potential benefit of a naloxone reversal device, and contact the opioid prescriber if such a device is deemed appropriate.

Used alongside antidepressants, OTC analgesics and anti-inflammatories purchased from pharmacies may effectively treat patients with depression without increasing their risk of adverse events.

The transdermal buprenorphine manufacturer has launched an awareness campaign to address specific knowledge gaps among pharmacists that pertain to opioids.

Although pharmacies can legally dispense remaining refills of prescriptions for rescheduled hydrocodone combination products submitted prior to October 6, 2014, over the next 6 months, many drug chains have chosen not to honor those refills.

Patients with irritable bowel syndrome cannot block pain signals from the gut as easily as those without the gastrointestinal condition.

In response to the recent article by Gary M. Franklin, MD, MPH, titled "Opioids for chronic non-cancer pain: A position paper of the American Academy of Neurology," we wish to address a number of issues.

All drugs containing the opioid hydrocodone have been reclassified as Schedule II controlled substances, prohibiting pharmacies from recognizing refills and phoned-in prescriptions for those medications.

When quality of wallet takes precedence over quality of life, the healing arts suffer for it.

California joins 5 other states in allowing pharmacists to dispense naloxone without a prescription.

'The Holy Trinity' is a drug regimen that includes at least an opioid, a benzodiazepine, and carisoprodol.

Reclassifying hydrocodone will not stop the drug from being filled legitimately and sold illegally.

Just a dozen drug ingredients are the culprits behind nearly half of all emergency hospitalizations for unsupervised prescription drug ingestions among young children.

Alpha-2-macroglobulin may soon revolutionize the treatment of osteoarthritis.

The FDA today approved AstraZeneca's naloxegol (Movantik) treatment for opioid-induced constipation in adults with chronic noncancer pain.

The My GI Health tool tracks symptoms of gastroesophageal reflux disease over time, helping clinicians save time and improve patient care.

Providing patients with information is key to helping them manage sickle cell disease pain.

The community pharmacist's life is about to get a lot more difficult.

Updated REMS attempts to stem the flow of extended-release, long-acting opioids to addicts while ensuring patients in severe pain retain access.

A University of Kentucky pharmacy professor has developed a nasal spray of naloxone (Narcan) to treat potentially fatal overdoses from heroin and prescription opioids.

Drugs that contain hydrocodone will be moved to a more restrictive category of the Controlled Substances Act.

Aspirin not only prevents the production of pain-causing compounds in the body, but also triggers an enzyme to speed the reduction of inflammation.

Galleon Pharmaceuticals Corp's GAL-021 reverses and prevents respiratory depression associated with opioid use without affecting analgesia.

The Drug Enforcement Administration has officially placed tramadol, a centrally acting opioid analgesic, into schedule IV of the Controlled Substances Act.